Seoul National University · 医学
Professor Heung-Woo Park's research lab focuses on respiratory and metabolic diseases, with a strong emphasis on asthma pathogenesis, asthma phenotypes, and type 2 diabetes mellitus. The lab investigates key molecular mechanisms such as HMGB1 and ADRB2 variants in asthma, explores biomarkers for disease progression and treatment response, and evaluates the impact of medications like tiotropium and systemic corticosteroids on clinical outcomes. The lab also examines genetic and metabolic factors influencing disease exacerbations and treatment efficacy, particularly in vulnerable populations.
Figures are computed from collected data and may differ slightly.
Our findings suggest that HMGB1 plays a key role in the pathogenesis of clinical and experimental asthma characterized by eosinophilic airway inflammation.
As many as 30% of severe asthmatics on conventional medications with reduced lung function were found to respond to adjuvant tiotropium. The presence of Arg16Gly in ADRB2 may predict response to tiotropium.
These results suggest that addition of SCS to ICS increases the risk of HBV reactivation, especially when SCS are administered chronically or at high doses.
Change in body composition over time can be used to identify healthy middle-aged individuals at high risk for rapid FEV1 decline.
DA-1229 monotherapy (5 mg for 12 weeks) improved HbA1c, fasting plasma glucose level, OGTT results and β-cell function. This drug was well tolerated in Korean subjects with type 2 diabetes mellitus.
Asthma exacerbation (AE) usually denotes worsening of asthma symptoms that requires intense management to prevent further deterioration. AE has been reported to correlate with clinical and demographic factors, such as race, gender, and treatment compliance as well as environmental factors, such as viral infection, smoking, and air pollution. In addition, recent observations suggest that there are likely to be genetic factors specific to AE. Understanding genetic factors specific to AE is essenti
The response to drug treatment in asthma is a complex trait and is markedly variable even in patients with apparently similar clinical features. Pharmaco-genomics, which is the study of variations of human genome characteristics as related to drug response, can play a role in asthma therapy. Both a traditional candidate-gene approach to conducting genetic association studies and genome-wide association studies have provided an increasing list of genes and variants associated with the three major
The transcriptome represents the complete set of RNA transcripts that are produced by the genome under a specific circumstance or in a specific cell. High-throughput methods, including microarray and bulk RNA sequencing, as well as recent advances in biostatistics based on machine learning approaches provides a quick and effective way of identifying novel genes and pathways related to asthma, which is a heterogeneous disease with diverse pathophysiological mechanisms. In this manuscript, we brie
Asthma is not rare in elderly people (≥65).1 Although we are in an era of declining overall asthma mortality, mortality remains high within this particular population.2 There are important gaps in the current state of knowledge regarding the natural history and exacerbation of asthma in elderly people. To reduce these gaps, a prospective, observational, multicenter cohort with 5-year (2009–2013) follow-up was established. This report is the result of the first year of follow-up. The goal of the
Open papers in the app to read, cite, and organize with AI.
